CURRICULUM VITAE

Professor Kleopas A. KLEOPA, MD, FAAN

6 Iroon Avenue
P.O. Box 23462, 1683 Nicosia, Cyprus
Phone: +357-99353544, +357-22358600, Email: kleopa@cing.ac.cy

Current positions

Senior Consultant Neurologist
Head of Neuroscience Department
Professor, Cyprus School of Molecular Medicine
Coordinator, Neuroscience Graduate Program
Coordinator, Center for Neuromuscular Disorders
Center for Multiple Sclerosis and Related Disorders
The Cyprus Institute of Neurology and Genetics

PERSONAL INFORMATION

Date of birth : May 9, 1968
Marital status: Married, one child
Nationality: Cyprus

EDUCATION

1987-1993 Medical Studies, University of Würzburg Medical School, Germany

29/10/1993 Medical Degree (grade: “very good”), University of Würzburg Medical School, Germany

1991-1994 Doctoral Thesis Project in the Psychiatry - Laboratory of Clinical Neurochemistry, University of Würzburg, Germany

Title: «“Quantitative autoradiographic examination of Adenosin-A1 receptors in post-mortem human hippocampus” (*original in German*: “Quantitative Autoradiographische Untersuchung von Adenosin-A1-Rezeptoren im postmortem mensclichen Hippocampus”)

18/08/1994 Doctor of Medicine Title Award (grade: “*magna cum laude*”), Medical Faculty of the University of Würzburg

POSITIONS HELD AND ACADEMIC EXPERIENCE

1/2015 Coordinator, Neuroscience Postgraduate Program at the Cyprus School of Molecular Medicine

9/2012- Honorary Professor in Neurology, St. Georges University of London Medical School at the University of Nicosia

2/2012- Professor, Cyprus School of Molecular Medicine

11/2007-	Head of Neurology Clinic and Neuroscience Laboratory, Cyprus Institute of Neurology and Genetics
9/2002-	Senior Consultant Neurologist, Cyprus Institute of Neurology and Genetics
2001/02	Clinical Instructor of Neurology, University of Pennsylvania Medical Center, Philadelphia, USA
2000-2002	Postdoctoral Research Fellowship, Funded by National Multiple Sclerosis Society, University of Pennsylvania
1999-2001	Participation in Muscular Dystrophy Association (MDA) Clinic, Children's Hospital of Philadelphia
2000-2001	Patient Oriented Research Training Program, University of Pennsylvania, Clinical Research Center
1999-2001	Clinical Fellowship in EMG and Neuromuscular Disorders, University of Pennsylvania Medical Center, Philadelphia
1-6/1999	Chief Resident in Neurology, Medical College of Pennsylvania and Hahnemann/Drexel University, Philadelphia
1996-1999	Resident in Neurology, Medical College of Pennsylvania and Hahnemann/Drexel University, Philadelphia
1995-1996	Internship in Internal Medicine, Medical College of Pennsylvania, Philadelphia, USA
1994-1995	Internship in Neurology, Neurological Clinic of the University, Würzburg, Germany

Professional licenses and specialist board certification

1995	License to practice medicine in Germany
1999	Medical License for the State of Pennsylvania, USA
2000	Registration as a Medical Doctor in Cyprus
2000	Recognition as a Specialist Neurologist, Ministry of Health, Cyprus
2002	Diplomate, American Board of Psychiatry and Neurology, Inc.

Languages spoken

Greek (mother language), English, German (professionally fluent)

ADMINISTRATIVE EXPERIENCE

The Cyprus Institute of Neurology and Genetics

2002-	Member of the Scientific Council of the Cyprus Institute of Neurology and Genetics (CING)
2004-	Member of the Scientific Council Academic Affairs Committee, CING
2005-	Chair of the Library Committee, CING

2005 Member of the Ad Hoc Committee of the Board of Directors for the Selection of the new Medical Director for CING

2003- Responsible for the organization, staffing and funding of the Neuroscience Laboratory (currently 4 postdocs, 5 graduate students), CING

2004-05 Member of the Ad Hoc Committee of the Board of Directors for the conclusion of a cooperation agreement between the University of Cyprus and CING

2007-19 Head, Neurology Clinic E, CING (supervising junior neurologist, nursing and supportive staff)

2008- Director of the Transgenic and Experimental Mice Facility at CING (serving as National Core Facility both internal and external Users, currently staffed by 2 scientific and 3 supportive personnel)

2014- Member of the Committee of the Board of Directors for the communication with patient groups)

2011 Member of the Board of Directors Tender Board

2014- Coordinator of the 1-year Residency program, including training and evaluating neurology and psychiatry Residents

2018- Chairman of the Academic and Educational Affairs Committee, CING

Cyprus School of Molecular Medicine

2015- Member of the School Council

2015- Member of the School Academic Committee

2015- Member of the Neuroscience Admissions Committee

2015- Member of the Quality Assurance Committee

2018- Member of the MSc and PhD programs Admissions Committee

Other administrative and academic experience

2004-2014 Member of the Board of the Cyprus Neurological Society

2006-2011 President of the Bioethics Review Committee for Biomedical Research

2015- Member of the Cyprus National Bioethics Committee

2015-19 Member of the Advisory Committee of the Pharmaceutical Services/Ministry of Health for Multiple Sclerosis treatments

2010-14 Cyprus representative in the European Union of Medical Specialties (UEMS)-Section of Neurology

2011-13 Cyprus representative in the EU Program Committee Health for FP7

2011-13 Cyprus representative in the EU Innovative Medicines Initiative (IMI)

2015- Review Panel Expert for «Medical and Health Sciences» of the European Co-operation in the Field of Scientific and Technical Research - COST Association

2005- Scientific Advisor, Cyprus Myasthenia Gravis Patient Association

2018- Scientific Advisory Board Member, Charcot-Marie-Tooth Association USA

2019- Elected Member of the Board of Directors, International Charcot-Marie-Tooth and Related Neuropathies (CMTR) consortium

2019- Scientific Advisory Board Member, Gene Therapy Initiative for Neurofibromatosis 1

Professional Memberships and Other Academic Activities

2002 Diplomate, American Board of Psychiatry and Neurology, Inc

1996- Member of the American Academy of Neurology

2000- Member of the American Association of Neuromuscular and Electrodiagnostic Medicine

2002- Member of the Cyprus Neurological Society

2003- Member of the Society for Neuroscience (USA)

2003- Founding Member of the Cyprus Society of Human Genetics

2004-14 Member of the Board of the Cyprus Neurological Society

2005- Member of the World Muscle Society

2005- Scientific Advisor, Cyprus Myasthenia Gravis Association

2005- Member of the European Academy of Neurology

2008- Member of the Peripheral Nerve Society

2010- Member of the International Society of Neuroimmunology

2006-09 President of the Cyprus Bioethics Review Committee for Biomedical Research

2010-14 Cyprus representative in the European Union of Medical Specialties (UEMS)-Section of Neurology

2011-13 Cyprus representative in the EU Program Committee Health for FP7

2011-13 Cyprus representative in the EU Innovative Medicines Initiative (IMI)

2015- Member of the Cyprus National Bioethics Committee

2018- Member of the Scientific Advisory Board, Charcot-Marie-Tooth Association (CMTA) USA

2019- Elected Board Member of the International Charcot-Marie-Tooth and Related Disorders (CMTR) Consortium/Peripheral Nerve Society

2019- Elected Fellow of the American Academy of Neurology (FAAN)

HONORS AND AWARDS

1987-1989 Scholarship of the Cyprus Government to attend Medical School

1990-1993 Scholarship of the German Academic Exchange Service (DAAD)

1990 Participation in Erasmus Program for medical students with distinction in Neuroscience, Leiden, the Netherlands

1999	Neurology Teaching Award from Medical Students, Class of 1999, MCP-Hahnemann University
2000-2003	Advanced Postdoctoral Fellowship Award, National Multiple Sclerosis Society USA
2000-2002	Development Grant Award, USA Muscular Dystrophy Association
2004	Nominated member of the European Science Foundation Steering committee for Networking Neurosciences
2009	Fellowship Award, International Peripheral Nerve Society 2009 Meeting
2016-19	Member of the European Science Foundation (ESF) College of Expert Reviewers
2015	European Academy of Neurology Investigator Award 2015 from the Scientific Subspecialty Panel on Neuropathies
2017	Cyprus National Distinguished Researcher Award, Research Promotion Foundation
2019	Elected Fellow of the American Academy of Neurology

REVIEW OF SCIENTIFIC WORK and CONTRIBUTION TO SCIENCE

A central objective of my research activities in the last 18 years has been the investigation of cellular and molecular mechanisms that lead to the manifestation of neuropathy and encephalopathy in patients with inherited mutations in the gap junction protein connexin32 (Cx32), causing X-linked Charcot-Marie-Tooth Disease (CMT1X). While all of these patients develop peripheral neuropathy, CNS phenotypes occur only in a subset, for reasons that are not well understood. Gap junctions are crucial for the ability of glia cells and neurons to maintain active communication and to preserve homeostasis in the functioning nervous system. Through a series of publications, we have elucidated the repertoire of Schwann cell and oligodendroglial gap junction protein expression, their anatomic and functional relationship and possible interactions in health and disease. I contributed the discovery of Cx29 in glial cells, and I generated novel mouse models expressing Cx32 mutations in CNS and PNS, clarifying the loss of function mechanism involved. Furthermore, I described the early axonal pathology in models of CMT1X and characterized novel Cx32 mutations. *Related publications*:

a. Kleopa KA, Yum SW, Scherer SS (2002) Cellular mechanisms of connexin32 mutations associated with CNS manifestations. *J. Neurosci. Res.* 68:522-534.

b. Altevogt BM*, Kleopa KA*, Postma FR, Scherer SS, Paul DL (2002) Connexin29 Is Uniquely Distributed within Myelinating Glial Cells of the Central and Peripheral Nervous Systems *J. Neurosci.,* 22: 6458-6470. (*equal contribution)

c. Kleopa KA, Orthmann JL, Enriquez A, Paul DL, Scherer SS (2004) Unique distribution of gap junction proteins connexin29, connexin32, and connexin47 in oligodendrocytes, *Glia,* 47:346-57.

d. Sargiannidou I, Vavlitou N, Aristodemou S, Hadjisavvas A, Kyriacou K, Scherer SS, Kleopa KA (2009). Connexin32 mutations cause loss of function in Schwann cells and oligodendrocytes leading to PNS and CNS myelination defects. *J Neurosci*, 29:4748-4761.

e. Sargiannidou I, Kim GH, Kyriakoudi S, Eun BL, Kleopa KA. (2015) A start codon CMT1X mutation associated with transient encephalomyelitis causes complete loss of Cx32. *Neurogenetics*, 16:193-200.
f. Olympiou M, Sargiannidou I, Markoullis K, Karaiskos C, Kagiava A, Kyriakoudi S, Abrams CK, Kleopa KA (2016). Systemic inflammation disrupts oligodendrocyte gap junctions and induces ER stress in a model of CNS manifestations of X-linked Charcot-Marie-Tooth disease. *Acta Neuropathol Commun*. Sep 1;4(1):95.
g. Kyriakoudi S, Sargiannidou I, Kagiava A, Olympiou M, Kleopa KA (2017) Golgi-retained Cx32 mutants interfere with gene addition therapy for CMT1X. Hum Mol Genet. 2017 26:1622-163.

2. In addition to clarification of the molecular mechanisms of CMT1X neuropathy and encephalopathy, and based on results from this work, we have recently developed novel gene therapy approaches to replace connexin genes specifically in myelinating glial cells of the peripheral and central nervous systems. Using relevant models of neuropathy and leukodystrophy, we have explored world-wide innovative gene therapy approaches using lentiviral and AAV vectors for cell-targeted expression based on cell-specific and myelin-specific promoters. *Related publications*:
a. Kagiava A, Sargiannidou I, Bashiardes S, Richter J, Schiza N, Christodoulou C, Gritti A, Kleopa KA. (2014) Gene delivery targeted to oligodendrocytes using a lentiviral vector. *J Gene Med*. 16(11-12):364-73.
b. Schiza N., Sargiannidou I., Kagiava A., Karaiskos C., Nearchou M., Kleopa KA (2015) Transgenic replacement of Cx32 in gap junction deficient oligodendrocytes rescues the phenotype of a hypomyelinating leukodystrophy model. *Hum Mol Genet*, 24: 2049-64.
c. Sargiannidou I, Kagiava A, Bashiardes S, Richter J, Christodoulou C, Scherer SS, Kleopa KA (2015) Intraneural GJB1 gene delivery improves nerve pathology in a model of CMT1X. *Annals of Neurology*, 78:303-316.
d. Kagiava A, Sargiannidou I, Theophilidis G, Karaiskos C, Richter J, Bashiardes S, Schiza N, Nearchou M, Christodoulou C, Scherer SS, Kleopa KA (2016) Intrathecal gene therapy rescues a model of demyelinating peripheral neuropathy. *Proc Natl Acad Sci U S A,* 113 (17):e2421-9.
e. Georgiou E, Sidiropoulou K, Richter J, Papaneophytou C, Sargiannidou I, Kagiava A, von Jonquieres G, Christodoulou C, Klugmann M, Kleopa KA (2017) Gene therapy targeting oligodendrocytes provides therapeutic benefit in a leukodystrophy model, *Brain,* 140:599-616.
f. Kagiava A, Karaiskos C, Richter J, Tryfonos C, Lapathitis G, Sargiannidou I, Christodoulou C, Kleopa KA (2018). Intrathecal gene therapy in mouse models expressing CMT1X mutations. Hum Mol Genet. 27: 1460-1473.
g. Schiza N, Georgiou E, Kagiava A, Médard J-J, Richter J, Tryfonos C, Sargiannidou I, Heslegrave AJ, Rossor AM, Zetterberg H, Reilly MM, Christodoulou C, Chrast R, Kleopa KA (2019). Gene replacement therapy in a model of Charcot-Marie-Tooth 4C neuropathy, *Brain*. 2019 May 1;142(5):1227-1241.
h. Kagiava A, Richter J, Tryfonos C, Karaiskos C, Heslegrave AJ, Sargiannidou I, Rossor AM, Zetterberg H, Reilly MM, Christodoulou C, **Kleopa** KA. Gene replacement therapy after neuropathy onset provides therapeutic benefit in a model of CMT1X. Hum Mol Genet. 2019, 28: 3528-3542.

3. A further line of research in my lab has been the study of glial connexin pathology in acquired demyelination, using for study both multiple sclerosis postmortem human brain samples as well as the experimental encephalomyelitis (EAE) mouse model.

Detailed analysis of disease brain samples has shown widespread glial connexin pathology with loss of gap junctions in oligodendrocytes not only in white and gray matter lesions, but also in normal appearing tissue and in parallel development of astrogliosis and disconnection of astrocytes from oligodendrocytes. These changes correlate with inflammation and disease progression. Current ongoing work investigates the EAE mechanisms in highly active MS brain and in connexin deficient mouse models. *Related publications*:

a. Markoullis K, Sargiannidou I, Gardner C, Hadjisavvas A, Reynolds R, Kleopa KA (2012) Disruption of oligodendrocyte gap junctions in experimental autoimmune encephalomyelitis. *Glia*, 60:1053-66.
b. Markoullis K, Sargiannidou I, Schiza N, Hadjisavvas A, Roncaroli F, Reynolds R, Kleopa KA (2012) Gap junction pathology in multiple sclerosis lesions and in normal appearing white matter. *Acta Neuropathol*, 123:873-86.
c. Markoullis K, Sargiannidou I, Schiza N, Roncaroli F, Reynolds R, Kleopa KA (2014) Oligodendrocyte gap junction loss and disconnection from reactive astrocytes in multiple sclerosis grey matter. *J Neuropathol Exp Neurol*, 73(9):865-79*.*
d. Papaneophytou CP, Georgiou E, Karaiskos C, Sargiannidou I, Markoullis K, Mona Freidin M, Abrams CK, Kleopa KA (2018) Regulatory role of oligodendrocyte gap junctions in inflammatory demyelination. Glia, 66(12):2589-2603*.*
e. Papaneophytou C, Georgiou E, Kleopa KA. The role of oligodendrocyte gap junctions in neuroinflammation. Channels (Austin). 2019 Dec;13(1):247-263. doi: 10.1080/19336950.2019.1631107.

4. My research has also contributed to the understanding of autoimmune and paraneoplastic disorders presenting with neuromyotonia and encephalitis, focusing on the common molecular mechanism of potassium channel dysfunction, either directly or indirectly through immune-mediated alterations of associated molecules. We have contributed to the identification of the antigenic targets and phenotypes involved. *Related publications*:

a. Kleopa KA, Elman L, Lang B, Vincent A, Scherer SS (2006). Neuromyotonia and limbic encephalitis sera target mature *Shaker*-type K+ channels: subunit specificity correlates with clinical manifestations. *Brain,* 129:1570-84.
b. Vincent A, Lang B, Kleopa KA (2006). Autoimmune channelopathies and related neurological disorders. *Neuron*, 52:123-138.
c. Irani SR, Alexander S, Waters P, Kleopa KA, Pettingill P, Zuliani L, Peles E, Buckley C, Lang B, Vincent A (2010) Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-2-associated protein in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. *Brain*, 133:2734-2748.
d. Irani SR,* Pettingill P,* Kleopa KA,* Schiza N, Waters P, Mazia C, Zuliani L, Watanabe O, Lang B, Buckley C, Vincent A (2012) Morvan's syndrome: clinical and serological observations in 29 cases. *Annals of Neurology*, 72:241-55 (*:*joint first authors*)

5. In addition, I have contributed to several research projects focusing on diagnosis and treatment of neurological and especially neuromuscular disorders, including myasthenia, ALS and peripheral neuropathies, as evident in the my numerous peer reviewed and highly cited publications (below).

RESEARCH GRANTS OBTAINED

2000-02 Advanced Postdoctoral Fellowship Award (FA 1393-A-1), National Multiple Sclerosis Society: Connexin32 mutations and central demyelination ($ 87,319)

2002-04 Advanced Postdoctoral Fellowship Award (FA 1393-A-1), National Multiple Sclerosis Society: Connexin32 mutations and central demyelination ($ 87,319)

2003 Grant of the Research Promotion Foundation of Cyprus for the participation in the 6th EU Framework program (5,000 CYP)-PI

2004-07 Telethon Grant for the Study of CNS manifestations in CMTX (24,675 CYP)

2004-09 Research Grant (RG 3457A2/1) National Multiple Sclerosis Society "CNS connexins and demyelination in CMTX" ($ 219,750)-PI

2007-09 Research Grant of the Research Promotion Foundation: "Models of demyelinating neuropathy and encephalopathy" (90,000 CYP)-PI

2007-09 Bilateral Grant of the Research Promotion Foundation" Investigation of the molecular mechanisms of nervous system hyperexcitability in animal models" (CYP 10,350)-PI

2007-11 Participation in COST action of the European Science Foundation (MYELINET)

2008-10 Research Grant of the Research Promotion Foundation: "The role of gap junctions in Multiple Sclerosis" (120,000 Euro)-PI

2010-12 Research Grant of the Research Promotion Foundation (Access to Infrastructure Grant): "Gap junction pathology in Multiple Sclerosis brain" (40,000 Euro)-PI

2010-12 Telethon Grant "Developing new treatments for CMT1X neuropathy" (100,000 Euro)-PI

2011-13 Research Grant of the Research Promotion Foundation: "Gene therapy for CMT1X inherited demyelinating neuropathy" (180,000 Euro)-PI

2011-16 Research Grant Award from the European Leukodystrophy Association (ELA) entitled "Gene therapy for hypomyelinating leukodystrophy" (194,000 Euro for 3 years)- PI

2013-15 Research Grant Award from the Muscular Dystrophy Association, USA (MDA) entitled "Mechanisms of CNS disease in X-linked Charcot-Marie-Tooth Disease" (100,200 US Dollars for Kleopa lab for 2 years)- co-PI

2013-16 Research Grant Award (277250) from the Muscular Dystrophy Association, USA (MDA) entitled "Developing Gene Therapy for Inherited Neuropathy" (280,945 US Dollars for 3 years)- PI

2013-17 Research Grant (RG 3457A2/1) National Multiple Sclerosis Society "Roles of Cx32 and Cx47 in oligodendrocytes" ($ 240,830 USD for Kleopa lab)-co-PI

2016-18 Research Grant from the Charcot-Marie-Tooth Association (CMTA) "Evaluating the outcome of a gene replacement approach in a model of CMT4C neuropathy" ($110,424 for 2 years)- PI

2016-18 Research Grant from the French Muscular Dystrophy Association-AFM - "A gene therapy approach for treating CMT4C neuropathy" (€110,000 for 2 years)-PI

2017-19 Research Grant Award (480030) from the Muscular Dystrophy Association, USA (MDA) – co-funded by the CMT Association- entitled "Expanding the gene therapy approach for treating CMT1X" ($120,000)- PI

2019-22 Research Grant Award (603003) co-funded by the from the Muscular Dystrophy Association, USA (MDA) –CMT Association- entitled "A translatable gene therapy approach to treat CMT1X" ($276,430)- PI

2019-21 Research Grant Award "Development of gene silencing approach to treat CMT1A" – CMT Research Foundation ($99000, PI).

2019-21 Research Grant from the Charcot-Marie-Tooth Association (CMTA) "AAV mediated Gene Therapy for CMT4C" ($122,100 for 2 years)- PI

Conferences Organized

12/2008	International Conference: Myasthenia, Diagnosis and Treatment, Nicosia, Cyprus
3/2009	Mediterranean Society of Myology 9th Meeting, Nicosia, Cyprus
5/2010	Scientific Conference on Multiple Sclerosis, The Cyprus Institute of Neurology and Genetics
7/2012	Innovative Medicines Initiative (IMI) Information Day- co-organized with the Cyprus Research and Development Pharmaceutical Association, Nicosia
11/2012	XIIth NeuroMediterranean Congress of Neurology, Nicosia, Cyprus
5/2013	Information Day: Novel Gene Therapy Perspective for Neurological Disease, The Cyprus Institute of Neurology and Genetics
10/2014	Member of the Scientific Committee, 3rd Annual Meeting of the Cyprus Society for Human Genetics, Nicosia 10-11/10, 2014
7/2015	Symposium Organizer, "Molecular and cellular changes in CNS myelinating glia during demyelination and remyelination" , XII European Meeting on Glial Cells in Health and Disease, Bilbao, Spain, July 15-18, 2015
5/2017	Scientific Committee Member, 2nd Hellenic Society of Gene Therapy and Regenerative Medicine, 26-27 May, Athens
12/2019	Hellenic Academy of Neuroimmunology- Symposium Organizer, Role of glia cells in neuroinflammation. Thessaloniki, Greece.

Ad hoc reviewer and editorial consultant for scientific journals

2000-	Muscle and Nerve
2002-	Journal of Neurology
2006-	Brain
2007-	Biotechnology Journal
2007-	BioMed Central Neurology
2007-	Journal of Inherited Metabolic Disease
2008-	Neuron Glia Biology
2009-	Acta Myologica
2009-	Journal of the Peripheral Nervous System
2010-	Journal of Neuroscience

2010-	PLoS Genetics
2010-	BBA – Biomembranes
2010-	Neurochemical Research
2011-	Journal of Neuropathology and Experimental Neurology
2011-	Acta Neuropathologica
2011-	Journal of the Neurological Sciences
2012-	Clinical Neurology and Neurosurgery
2012-	Journal of Pediatrics
2013-	PLoS ONE
2013-	Multiple Sclerosis and Related Disorders
2013-	Molecular Neurobiology
2013-	Human Molecular Genetics
2014-	BMC Neurology
2014-	Pediatrics
2014-	Cell Tissue Research
2015-	NeuroMolecular Medicine
2015-	Neurobiology of Disease
2016-	Scientific Reports
2016-	Experimental Brain Research
2017-	Neuroscience Letters
2017-	Neuromuscular Disorders
2017-	Glia
2017-	Gene Therapy
2018-	Nature Communications
2019-	Nucleic Acids research
2019-	Molecular Psychiatry
2019-	Journal of Clinical Investigation (JCI)

Reviewer for research funding organizations

2006-08	National Multiple Sclerosis Society, (USA
2007-15	The Wellcome Trust, UK
2010-15	AFM (Association Française contre les Myopathies), France
2010-13	European Science Foundation (ESF)
2011-16	French National Research Agency
2012-14	European Leukodystrophy Association (ELA), France
2014	Vaincre les Maladies Lysosomales (VML), France
2017	Review Panel Expert for «Medical and Health Sciences» of the European Co-operation in the Field of Scientific and Technical Research - COST Association COST-2016-2 and 2017 Review Panel Member
2015-	European Commission Horizon2020 Expert evaluator in Life Sciences Panel of the 2014-2015 and 2019 Marie Skłodowska-Curie Actions Evaluator for 2016 H2020 Health - Personalized Medicine projects
2016-19	Member of the European Science Foundation (ESF) College of Expert Reviewers, 2018, 2019 grant Evaluator
2017	Post-doctoral Grants Evaluator, Hellenic Foundation for Research and Innovation
2018	COST Action Assessment Reviewer
2019	Grant Evaluator, MS Society Australia ARSEP (French MS Association) grant review

Other Academic Activities

2014-19	Member of the External Evaluation Committee for the promotion of Academic staff at the University of Crete (2), University of Athens (3), University of Thessaly (1), University of Patra (1), and University of Thessaloniki (3), Greece.
2013	External Referee for the Academic promotion at the Department of Neurology, University of Pennsylvania Medical Center, Philadelphia, USA
2015	External referee for Academic promotion, San Raffaele Scientific Institute, Milan, Italy
2017	External Referee for Academic promotion at the Department of Neurology, University of Illinois, Chicago, USA
2015-18	Member of **PhD Exam committees** at the University of Cyprus (3), at the University of Crete (1), at Monash University, Australia (1), and at the Cyprus School of Molecular Medicine (11).
	Member of **MSc Exam committees** at the Cyprus School of Molecular Medicine (9)

TEACHING EXPERIENCE

Drexel (MCP-Hahnemann) University

1998-99	Weekly Neurology Lectures for medical students and neurology residents
1999	Lectures in Neurogenetics for neurology residents

University of Pennsylvania Medical Center

1999-02	Weekly neuromuscular conferences and case presentations for faculty, medical students and residents
1999-01	Neuromuscular disorders lectures for medical studentsand residents
1/2000	Pathophysiology course for medical students: Inflammatory Myopathies
2000-02	Brain and Behavior Course for Medical Students
2001-02	Clinicopathological conferences in brain and behavior course

The Cyprus Institute of Neurology and Genetics

2002-	Weekly neurology lectures for nursing staff
2008-	Weekly Lectures for Neurology Residents
2014-	Coordinating Training of Neurology and Psychiatry residents
2005-16	Providing Fellowship training of Neurologist in EMG/Neuromuscular Disorders (total 5 fellows trained) for periods of 3-12 months.

University of Cyprus

2010-12	Coordinator of the Neuroscience and Neurogenetics course for the Medical Genetics MSc/PhD degree jointly offered by the CING and the University of Cyprus/Dept. of Biological Sciences

2011-12 Supervision of 1 MSc Student in Medical Genetics (graduated 2012)

2011-15 Supervision of 1 PhD Student in Medical Genetics (graduated May 2015)

2016- Lectures (neurological examination, movement and reflexes) for 3rd and 4th year Medical Students

2016 Teaching of 4th year Medical Students rotating in Neurology

2017-18 Coordinator of the Neurology Lectures for 5th year Medical Students

2017-18 Coordinator of the Clinical Rotations in Neurology at the Cyprus Institute of Neurology and Genetics of 5th year Medical Students

2017- Special Scientist, University of Cyprus Medical School

Supervision of Students in the Neurology Clinic and in Neuroscience Laboratory in collaboration with other Universities

2005- Teaching undergraduate biology/biomedicine students for summer rotations (16) or for BSc project supervision (3)

2007-14 Supervision of postgraduate students (2 MSc and 2 PhD) for part of their research project

2012- Supervision and instruction of 2nd and 3rd year Medical Students rotating in Neurology, from the St. Georges University London Medical School at the University of Nicosia

2016- Supervision of 4th and 5th year Medical Students rotating in Neurology from the European University Cyprus

Cyprus School of Molecular Medicine

2012-14 Lectures in Molecular Medicine and Medical Genetics courses

2012- Supervision of MSc students (8) and PhD students (4, of whom 2 graduated in 2016-17)

2015- Program Coordinator, Neuroscience MSc/PhD program

2015- Course coordinator and teaching most of the Cellular and Molecular Neuroscience (NEURO101) course

Full papers in peer-reviewed scientific journals cited in PubMed–NCBI

(Total of over 5200 citations, h-index=33, last updated January 2020) in chronological order. Listed also in:

http://www.ncbi.nlm.nih.gov/pubmed/?term=kleopa

https://scholar.google.com/citations?user=uqguFR4AAAAJ&hl=en

1. Deckert J., Berger W., **Kleopa K**., Heckers S., Ransmayr G., Heinsen H., Beckmann H. and Riederer P. (1993) Adenosine A1 receptors in human hippocampus: Inhibition of (3H)8 cyclopentyl 1,3 dipropylxanthine binding by antagonist drugs. Neurosci. Lett. 150: 191 194.
2. **Kleopa K**., Becker G., Roggendorf W. and Reichmann H. (1996) Primary T cell lymphoma of the cerebellum. J. Neurooncol. 27: 225 230.

3. **Kleopa K.A.,** Sherman M., Neal B., Heiman-Patterson T. (1999) Bipap improves survival and pulmonary function decline in patients with ALS. J. Neurol. Sci. 164: 82-88.
4. **Kleopa K.A.,** Teener J.W., Scherer S.S., Galetta S.L., Bird S.J. (2000) Chronic multiple paraneoplastic syndromes. Muscle Nerve. 23: 1767-1772.
5. **Kleopa K.A**., Rosenberg H., Heiman-Patterson T. (2000) Becker's Muscular Dystrophy
6. **Kleopa K.A**., Raizen D.M., Friedrich C.A., Brown M.J., Bird S.J. (2001) Acute axonal neuropathy in maple syrup urine disease. Muscle Nerve 24: 284-287.
7. Rainier S., Hedera P, Alvarado D., Zhao X., **Kleopa K.A**., Heiman-Patterson T., Fink J.K. (2001) Hereditary spastic paraplegia linked to chromosome 14q11-q21: reduction of the SPG3 locus interval from 5.3 to 2.7 cM. J. Med. Genet. 38(11):E39.
8. **Kleopa K.A**., Yum S.W., Scherer S.S. (2002) Cellular mechanisms of connexin32 mutations associated with CNS manifestations. J. Neurosci. Res. 68:522-534.
9. **Kleopa K.A.,** Scherer S.S. (2002). Inherited Neuropathies. Neurol. Clin. North America. 20(3):679-709.
10. Altevogt B.M.*, **Kleopa K.A.***, Postma F.R., Scherer S.S., Paul D.L. (2002) Connexin29 Is Uniquely Distributed within Myelinating Glial Cells of the Central and Peripheral Nervous Systems J Neurosci, 22: 6458-6470. (* authors contributed equally to the work)
11. **Kleopa K.A.,** Barchi R.L. (2002) Genetic disorders of neuromuscular ion channels. Muscle Nerve. 26:299-325.
12. **Kleopa K.A.,** Sutton L.N., Ong J., Tennekoon G., Telfeian A.E. (2002) Conus-cauda compression from nerve root hypetrophy in a child with Dejerine-Sottas syndrome: Improvement with laminectomy and duraplasty. J Neurosurg (Spine), 97:244-247.
13. Yum S.W., **Kleopa K.A**., Shumas, S., Scherer S.S. (2002) Diverse trafficking abnormalities of Connexin32 mutants causing CMTX. Neurobiol Dis, 11:43-52.
14. Street V.A., Bennet C.L., Goldy J.D., Shirk A.J., **Kleopa K.A**., Tempel B.L., Lipe H.P., Scherer S.S., Bird T.D., Chance P.F. (2003) Mutation of a putative protein degradation gene LITAF/SIMPLE in Charcot-Marie-Tooth disease 1C. Neurology, 60: 22-26.
15. Heliopoulos, I. Patlakas G., Vadikolias, K., Artemis, N., **Kleopa K.A**., Maltezos, E., Piperidou C. (2003) The maximal voluntary ventilation in myasthenia gravis. Muscle Nerve, 27:715-719.
16. **Kleopa K.A**., Zamba-Papanicolaou E., Kyriakides T. (2003) Lumbar compressive myelopathy presenting as segmental motor neuron disease. Muscle Nerve, 28:69-73.
17. Devaux J., **Kleopa K.A**., Cooper E.C., Scherer S.S., (2004) KCNQ2 is a nodal K+ channel, J Neurosci,24:1236-1244.

18. Papathanasiou ES, Zamba-Papanicolaou E, Pantzaris M, **Kleopa KA**, Kyriakides T, Papacostas S, Pattichis C, Iliopoulos I, Piperidou C (2004) Neurogenic vestibular evoked potentials using a tone pip auditory stimulus. Electromyogr Clin Neurophysiol, 44:167-173.
19. **Kleopa K.A**., Kyriakides T. (2004) Lower lip dystonia: a new phenotypic variant of cranial movement disorder. Movement Disorders, 19:663-666.
20. Papathanasiou ES, Pantzaris M, Zamba-Papanicolaou E, Kyriakides T, **Kleopa KA**, Iliopoulos I, Piperidou C, Papacostas S (2004) Neurogenic vestibular evoked potentials in the diagnosis of Multiple Sclerosis. Electromyogr Clin Neurophysiol, 44:313-317.
21. **Kleopa KA**, Georgiou D-M, Nicolaou P, Koutsou L, Papathanasiou E, Kyriakides T, Christodoulou K. (2004) A novel PMP22 mutation Ser22Phe in a family with HNPP and CMT1A phenotypes, Neurogenetics, 5:171-175.
22. **Kleopa K.A**., Orthmann J.L., Enriquez A., Paul D.L., Scherer S.S. (2004) Unique distribution of gap junction proteins connexin29, connexin32, and connexin47 in oligodendrocytes, Glia, 47:346-57.
23. Papathanasiou, E, **Kleopa K.A**., Pantzaris M (2004) Unobtainable radial nerve F-waves in a case of radial nerve conduction block. Electromyogr Clin Neurophysiol, 44:451-454.
24. **Kleopa KA**, Kyriacou K, Zamba-Papanicolaou E., Kyriakides T. (2005) Reversible inflammatory and vacuolar myopathy with vitamin E deficiency in celiac disease, Muscle Nerve,31:260-265.
25. Papathanasiou ES, Piperidou C, Iliopoulos I, Malekidou A, Katelari-Theocharidou E, Kyriakides T, **Kleopa KA**, Papacostas S (2005) Neurogenic vestibular evoked potentials in three cases of vestibular system dysfunction. Electromyogr Clin Neurophysiol, 45:39-45.
26. Papathanasiou E., Loizides A, Panayiotou P, Papacostas S, **Kleopa KA** (2005) Ulnar neuropathy at Guyon's Canal: Electrophysiological and surgical findings. Electromyogr Clin Neurophysiol, 45:87-92.
27. Papathanasiou ES, Piperidou C, Pantzaris M, Iliopoulos I, Petsa M, Kyriakides T, **Kleopa KA**, Papacostas S (2005) Vestibular symptoms and signs are correlated with abnormal neurogenic vestibular evoked potentials in patients with multiple sclerosis. Electromyogr Clin Neurophysiol, 45:195-201.
28. **Kleopa KA**, Zamba-Papanicolaou E, Alevra X, Nicolaou P, Georgiou D-M, Hadjisavvas A, Kyriakides T, Christodoulou K (2006). Phenotypic and cellular expression of two novel Connexin32 mutations causing CMT1X. Neurology, 66:396-402.
29. **Kleopa KA**, Drousiotou A, Mavrikiou E, Ormiston A, Kyriakides T (2006). Naturally occurring utrophin correlates with disease severity in Duchenne Muscular Dystrophy. Hum Mol Genet, 15:1623-8.
30. Stern BV, Baehring JM, **Kleopa KA**, Hochberg FH (2006). Multifocal motor neuropathy with conduction block associated with metastatic lymphoma of the nervous system. J Neuroocol, 78:81-4.

31. **Kleopa KA**, Elman L, Lang B, Vincent A, Scherer SS (2006). Neuromyotonia and limbic encephalitis sera target mature Shaker-type K+ channels: subunit specificity correlates with clinical manifestations. Brain, 129:1570-84.

32. **Kleopa KA**, Scherer, S.S (2006) Molecular genetics of X-linked Charcot-Marie-Tooth disease. Neuromolecular Med, 8:107-122.

33. Vincent A, Lang B, **Kleopa KA** (2006). Autoimmune channelopathies and related neurological disorders. Neuron, 52:123-138.

34. Bataller L, **Kleopa KA**, Wu GF, Rossi JE, Rosenfeld MR, Dalmau J (2007). Autoimmune Limbic Encephalitis in 39 Patients: Immunophenotypes and Outcomes. J Neurol Neurosurg Psychiatry, 78: 381-385.

35. Sargiannidou I, Ahn M, Enriquez AD, Peinado A, Reynolds R, Abrams CK, Scherer SS, **Kleopa, KA** (2008). Human oligodendrocytes express Cx31.3: function and interactions with Cx32 mutants. Neurobiol Dis, 30: 221-233.

36. Savvaki M, Panagiotaropoulos T, Stamatakis A, Sargiannidou I, Karatzioula P, Watanabe K, Stylianopoulou F, Karagogeos D, **Kleopa KA** (2008). Impairment of learning and memory in TAG-1 deficient mice associated with shorter CNS internodes and disrupted juxtaparanodes. Mol Cell Neurosci, 39:478-490.

37. Mintchev N, Zamba-Papanicolaou E, **Kleopa KA**, Christodoulou K (2009) A novel ALS2 splice-site mutation in a Cypriot Juvenile Primary Lateral Sclerosis family. Neurology, 72:28-32.

38. **Kleopa KA**, Natsiopoulos K (2009) Acute cervical radiculopathies in spontaneous intracranial hypotension. J Neurology, 256(3):499-501.

39. Sargiannidou I, Vavlitou N, Aristodemou S, Hadjisavvas A, Kyriacou K, Scherer SS, **Kleopa KA** (2009). Connexin32 mutations cause loss of function in Schwann cells and oligodendrocytes leading to PNS and CNS myelination defects. J Neurosci, 29:4736-4749.

40. Spanaki C, Zaganas I, **Kleopa KA**, Plaitakis A (2010) Human GLUD2 Glutamate Dehydrogenase is Expressed in Mitochondria of Neural and Testicular Supporting Cells, J. Biol. Chem. 285:16748-56.

41. Sargiannidou, I, Markoullis, K, **Kleopa KA** (2010) Molecular mechanisms of gap junction mutations in myelinating cells. Histol Histopathol. 25:1191-1206.

42. Nicolaou P, Zamba-Papanicolaou E, Koutsou P, **Kleopa KA**, Georghiou A, Hadjigeorgiou G, Papadimitriou A, Kyriakides T, Christodoulou K (2010) Charcot-Marie-Tooth disease in the Cypriot population: epidemiological, clinical and genetic characteristics. Neuroepidemiology, 35(3):171-177.

43. **Kleopa KA**, Orthmann-Murphy JL, Sargiannidou, I (2010) Gap junction disorders of myelinating cells, Reviews Neurosci, 21 (5): 397-419.

44. Vavlitou, N, Sargiannidou, I, Markoullis, K, Kyriacou K, Scherer SS, **Kleopa KA** (2010) Axonal pathology precedes demyelination in a mouse model of CMT1X neuropathy, J Neuropathol Exp Neurol, 69 (9): 945-958.

45. Irani SR, Alexander S, Waters P, **Kleopa KA**, Pettingill P, Zuliani L, Peles E, Buckley C, Lang B, Vincent A (2010) Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-2-

associated protein in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain, 133:2734-2748.

46. **Kleopa KA** (2011) Autoimmune Channelopathies of the Nervous System. Curr Neuropharmacol. 9:458-467.
47. **Kleopa KA** (2011) The role of gap junctions in Charcot-Marie-Tooth disease J Neurosci, 31:17753-17760.
48. Loukaides P, Schiza N, Pettingill P, Palazis L, Vounou E, Vincent A, **Kleopa KA** (2011) Morvan's syndrome caused by antibodies to multiple components of the voltage-gated potassium channel complex. J Neurol Sci, 312:52-6.
49. Irani SR,* Pettingill P,* **Kleopa KA**,* Schiza N, Waters P, Mazia C, Zuliani L, Watanabe O, Lang B, Buckley C, Vincent A (2012) Morvan's syndrome: clinical and serological observations in 29 cases. Annals of Neurology, 72:241-55 (*:joint first authors)
50. Markoullis K, Sargiannidou I, Gardner C, Hadjisavvas A, Reynolds R, **Kleopa KA** (2012) Disruption of oligodendrocyte gap junctions in experimental autoimmune encephalomyelitis. Glia, 60:1053-66.
51. Markoullis K, * Sargiannidou I, * Schiza N, Hadjisavvas A, Roncaroli F, Reynolds R, **Kleopa K**A (2012) Gap junction pathology in multiple sclerosis lesions and in normal appearing white matter. Acta Neuropathol, 123:873-86.
52. **Kleopa KA**, Abrams CK, Scherer SS (2012) How do Mutations in GJB1 Cause X-linked Charcot-Marie-Tooth Disease? Brain Res. 1487:198-205.
53. Votsi C, Zamba-Papanicolaou E, Georghiou A, Kyriakides T, Papacostas S, **Kleopa KA**, Pantzaris M, Christodoulou K Investigation of SCA10 in the Cypriot population: Further exclusion of SCA dynamic repeat mutations. J Neurol Sci. 2012;323(1-2):154-7.
54. Scherer SS, **Kleopa KA** (2012) X-linked Charcot-Marie-Tooth Disease. J Peripheral Nervous System, Suppl 3:9-13.
55. Zoupi L, Markoullis K, **Kleopa KA**, Karagogeos D (2013). Alterations of juxtaparanodal domains in two rodent models of CNS demyelination. Glia. 61:1236-49.
56. **Kleopa KA**, Sargiannidou I, Markoullis K (2013). Connexin pathology in chronic MS and EAE. Clin Exp Neuroimmunol. doi: 10.1111/cen3.12055, September 2013.
57. Zisimopoulou P, Evangelakou P, Tzartos J, Lazaridis K, Zouvelou V, Mantegazza R, Antozzi C, Andreetta F, Evoli A, Deymeer F, Saruhan-Direskeneli G, Durmus H, Brenner T, Vaknin A, Berrih-Aknin S, Frenkian Cuvelier M, Stojkovic T, Debaets M, Losen M, Martinez-Martinez P, **Kleopa KA**, Zamba-Papanicolaou E, Kyriakides T, Kostera-Pruszczyk A, Szczudlik P, Szyluk B, Lavrnic D, Basta I, Peric S, Tallaksen C, Maniaol A, Tzartos SJ. (2014) A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis. J Autoimmun. 52:139-45.
58. Tanteles GA, Spanou-Aristidou E, Antoniou C, Christophidou- Anastasiadou V, **Kleopa KA** (2014) Novel homozygous PANK2 mutation causing atypical

pantothenate kinase-associated neurodegeneration (PKAN) in a Cypriot family. J Neurol Sci,;340(1-2):233-6.

59. Markoullis K, Sargiannidou I, Schiza N, Roncaroli F, Reynolds R, **Kleopa KA** (2014) Oligodendrocyte gap junction loss and disconnection from reactive astrocytes in multiple sclerosis grey matter. J Neuropathol Exp Neurol, 73(9):865-79.

60. Kagiava A, Sargiannidou I, Bashiardes S, Richter J, Schiza N, Christodoulou C, Gritti A, **Kleopa KA**. (2014) Gene delivery targeted to oligodendrocytes using a lentiviral vector. J Gene Med. 2014 Nov;16(11-12):364-73.

61. **Kleopa KA**, Sargiannidou I. (2015) Connexins, gap junctions and peripheral neuropathy. Neurosci Lett. 596:27-32.

62. Schiza N., Sargiannidou I., Kagiava A., Karaiskos C., Nearchou M., **Kleopa KA** (2015) Transgenic replacement of Cx32 in gap junction deficient oligodendrocytes rescues the phenotype of a hypomyelinating leukodystrophy model, Hum Mol Genet, 24:2049-64.

63. Tanteles GA, Michaelidou S, Anastasiadou-Christophidou V, **Kleopa KA** (2015) Novel GLI3 mutation in a Greek-Cypriot patient with Greig cephalopolysyndactyly syndrome. Clin Dysmorphol, 24:102-5.

64. Sargiannidou I, Kim G-H, Kyriakoudi S, Eun B-L, **Kleopa KA** (2015) A start codon CMT1X mutation associated with transient encephalomyelitis causes complete loss of Cx32. Neurogenetics, 16:193-200.

65. Sargiannidou I, Kagiava A, Bashiardes S, Richter J, Christodoulou C, Scherer SS, **Kleopa KA** (2015) Intraneural GJB1 gene delivery improves nerve pathology in a model of CMT1X. Ann Neurol. 78:303-316.

66. Theotokis P, **Kleopa KA**, Touloumi O, Lagoudaki R, Lourbopoulos A, Nousiopoulou E, Kesidou E, Poulatsidou KN, Dardiotis E, Hadjigeorgiou G, Karacostas D, Cifuentes-Diaz C, Irinopoulou T, Grigoriadis N (2015). Connexin43 and connexin47 alterations after neural precursor cells transplantation in experimental autoimmune encephalomyelitis. Glia, 63:1772-83.

67. Tsonis AI, Zisimopoulou P, Lazaridis K, Tzartos J, Matsigkou E, Zouvelou V, Mantegazza R, Antozzi C, Andreetta F, Evoli A, Deymeer F, Saruhan-Direskeneli G, Durmus H, Brenner T, Vaknin A, Berrih-Aknin S, Behin A, Sharshar T, De Baets M, Losen M, Martinez-Martinez P, **Kleopa KA**, Zamba-Papanicolaou E, Kyriakides T, Kostera-Pruszczyk A, Szczudlik P, Szyluk B, Lavrnic D, Basta I, Peric S, Tallaksen C, Maniaol A, Casasnovas Pons C, Pitha J, Jakubíkova M, Hanisch F, Tzartos SJ (2015). MuSK autoantibodies in myasthenia gravis detected by cell based assay - A multinational study. J Neuroimmunol. 284:10-7.

68. Kagiava A, Theophilidis G, Sargiannidou I, Kyriacou K, **Kleopa KA** (2015). Oxaliplatin-induced neurotoxicity is mediated through gap junction channels and hemichannels and can be prevented by octanol. Neuropharmacology, 97:289-305.

69. Kastriti M, Sargiannidou I, **Kleopa, KA**, Karagogeos, D (2015). Differential Modulation of the Juxtaparanodal Complex in Multiple Sclerosis, Mol Cell Neurosci, 67:93-103.

70. **Kleopa KA** (2015): Carpal Tunnel Syndrome. In the Clinic Section. Annals of Internal Medicine, Sep 1;163(5):ITC1. doi: 10.7326/AITC201509010.

71. Spanaki C, Kotzamani D, **Kleopa** K, Plaitakis A. (2015) Evolution of GLUD2 Glutamate Dehydrogenase Allows Expression in Human Cortical Neurons. Mol Neurobiol. 2015 Sep 23. [Epub ahead of print]. PMID: 26399640

72. Kagiava A, Sargiannidou I, Theophilidis G, Karaiskos C, Richter J, Bashiardes S, Schiza N, Nearchou M, Christodoulou C, Scherer SS**, Kleopa KA** (2016). Intrathecal gene therapy rescues a model of demyelinating peripheral neuropathy. *Proc Natl Acad Sci U S A,* 113 (17):e2421-9.

73. Stergiou C, Lazaridis K, Zouvelou V, Tzartos J, Mantegazza R, Antozzi C, Andreetta F, Evoli A, Deymeer F, Saruhan-Direskeneli G, Durmus H, Brenner T, Vaknin A, Berrih-Aknin S, Behin A, Sharshar T, De Baets M, Losen M, Martinez-Martinez P, **Kleopa KA**, Zamba-Papanicolaou E, Kyriakides T, Kostera-Pruszczyk A, Szczudlik P, Szyluk B, Lavrnic D, Basta I, Peric S, Tallaksen C, Maniaol A, Gilhus NE, Casasnovas Pons C, Pitha J, Jakubíkova M, Hanisch F, Bogomolovas J, Labeit D, Labeit S, Tzartos SJ (2016) Titin antibodies in "seronegative" myasthenia gravis - A new role for an old antigen. *J Neuroimmunol*. 2016 Mar 15;292:108-15.

74. Olympiou M, Sargiannidou I, Markoullis K, Karaiskos C, Kagiava A, Kyriakoudi S, Abrams CK, **Kleopa** KA (2016). Systemic inflammation disrupts oligodendrocyte gap junctions and induces ER stress in a model of CNS manifestations of X-linked Charcot-Marie-Tooth disease. *Acta Neuropathol Commun*. 2016 Sep 1;4(1):95. doi: 10.1186/s40478-016-0369-5.

75. Georgiou E, Sidiropoulou K, Richter J, Papaneophytou C, Sargiannidou I, Kagiava A, von Jonquieres G, Christodoulou C, Klugmann M, **Kleopa KA** (2017) Gene therapy targeting oligodendrocytes provides therapeutic benefit in a leukodystrophy model, *Brain,* 140(3):599-616 (doi: 10.1093/brain/aww351) PMID: 28100454

76. Abrams CK, Goman M, Wong S, Scherer SS, **Kleopa** KA, Peinado A, Freidin MM (2017) Loss of Coupling Distinguishes GJB1 Mutations Associated with CNS Manifestations of CMT1X from Those Without CNS Manifestations. *Scientific Reports*. 2017 Jan 10;7:40166. doi: 10.1038/srep40166.

77. Kyriakoudi S, Sargiannidou I, Kagiava A, Olympiou M, **Kleopa** KA (2017) Golgi-retained Cx32 mutants interfere with gene addition therapy for CMT1X. *Hum Mol Genet*. 2017 26(9):1622-163

78. Konstantopoulos K, Christou Y-P, Vogazianos P, Zamba-Papanicolaou E, **Kleopa KA** (2017) A quantitative method for the assessment of dysarthrophonia in myasthenia gravis. *J Neurol Sci* 377:42–46

79. Demetriou CA, Hadjivasiliou PM, **Kleopa** KA, Christou YP, Leonidou E, Kyriakides T, Zamba-Papanicolaou E. (2017) Epidemiology of Amyotrophic Lateral Sclerosis in the Republic of Cyprus: A 25-Year Retrospective Study. *Neuroepidemiology*. 48(1-2):79-85.

80. Christou YP, Tanteles GA, Kkolou E, Ormiston A, Konstantopoulos K, Beconi M, Marshall RD, Plotkin H, **Kleopa** KA. (2017) Open-Label Fosmetpantotenate, a

Phosphopantothenate Replacement Therapy in a Single Patient with Atypical PKAN. *Case Rep Neurol Med*. 2017;2017:3247034. doi: 10.1155/2017/3247034.

81. Kagiava A, Karaiskos C, Richter J, Tryfonos C, Lapathitis G, Sargiannidou I, Christodoulou C, **Kleopa KA** (2018). Intrathecal gene therapy in mouse models expressing CMT1X mutations. *Hum Mol Genet,* 27:1460-1473.

82. Papaneophytou CP, Georgiou E, Karaiskos C, Sargiannidou I, Markoullis K, Mona Freidin M, Abrams CK, **Kleopa KA** (2018) Regulatory role of oligodendrocyte gap junctions in inflammatory demyelination. *Glia*, 66(12):2589-2603*.*

83. Schiza N, Georgiou E, Kagiava A, Médard J-J, Richter J, Tryfonos C, Sargiannidou I, Heslegrave AJ, Rossor AM, Zetterberg H, Reilly MM, Christodoulou C, Chrast R, **Kleopa KA** (2019). Gene replacement therapy in a model of Charcot-Marie-Tooth 4C neuropathy, *BRAIN,* 142(5):1227-1241.

84. Papaneophytou CP, Georgiou E, **Kleopa KA** (2019) Regulatory role of oligodendrocyte gap junctions in inflammatory demyelination. *Channels*, 13(1):247-263. doi: 10.1080/19336950.2019.1631107*.*

85. Kagiava A, Richter J, Tryfonos C, Karaiskos C, Heslegrave AJ, Sargiannidou I, Rossor AM, Zetterberg H, Reilly MM, Christodoulou C, **Kleopa** KA. Gene replacement therapy after neuropathy onset provides therapeutic benefit in a model of CMT1X. *Hum Mol Genet*. 2019, 28: 3528-3542.

86. Leonidou E, Pantzaris M, **Kleopa** KA, Loizidou MA, Kyriakides T, Christou YP. vA retrospective observational study of rituximab treatment in multiple sclerosis patients in Cyprus. Postgrad Med. 2019 Sep;131(7):486-489. doi: 10.1080/00325481.2019.1649975. Epub 2019 Jul 30.

87. Georgiou A, Demetriou CA, Christou YP, Heraclides A, Leonidou E, Loukaides P, Yiasoumi E, Pantziaris M, **Kleopa** KA, Papacostas SS, Loizidou MA, Hadjisavvas A, Zamba-Papanicolaou E. Genetic and Environmental Factors Contributing to Parkinson's Disease: A Case-Control Study in the Cypriot Population. Front Neurol. 2019 Oct 17;10:1047. doi: 10.3389/fneur.2019.01047. eCollection 2019.

88. Demetriou CA, Hadjivasiliou PM, **Kleopa** KA, Christou YP, Leonidou E, Kyriakides T, Zamba-Papanicolaou E. Retrospective longitudinal study of ALS in Cyprus: Clinical characteristics, management and survival. PLoS One. 2019 Sep 6;14(9):e0220246. doi: 10.1371/journal.pone.0220246. eCollection 2019.

89. Lambrianides S, Demetriou CA, Tillyris A, Kkolou E, Gaglia E, Agkastinioti E, Leonidou E, Christou YP, Papacostas SS, **Kleopa** KA, Kyriakides T, Pantzaris M. Prevalence of Anti-JC Virus (JCV) Antibodies in the Multiple Sclerosis (MS) Population in Cyprus: A Retrospective Study. Neurol Res Int. 2019 Aug 14;2019:3741260. doi: 10.1155/2019/3741260. eCollection 2019.

90. Sargiannidou I, Kagiava A, **Kleopa** KA. Gene therapy approaches targeting Schwann cells for demyelinating neuropathies. Brain Res. 2020 Feb 1;1728:146572. doi: 10.1016/j.brainres.2019.146572. Epub 2019 Nov 29.

Book chapters published

1. **Kleopa K**., Deckert J., Berger W., Heckers S., Ransmayr G., Heinsen H., Beckmann H. and Riederer P. (1993) Hemmung der Bindung von (3H)DPCPX in menschlichem Hippocampus durch Adenosin Rezeptor Antagonisten. In Baumann P (Ed.): "Biologische Psychiatrie der Gegenwart", Springer Verlag, Wien New York, pp.761 764.
2. **Kleopa K.A**., Brown M.J. (2000) Disability after “recovery” from GBS. GBS Newsletter, Guillan-Barré Syndrome Foundation International, Spring 2000, pp.7-8.
3. **Kleopa K.A**., Bird S.J. (2001) Carpal tunnel syndrome. Diseased-based module, Physicians Information and Education Resource, American College of Physicians-American Society of Internal Medicine. Published on line at http://pier.acponline.org.
4. **Kleopa K.A**., Barchi, R.L. (2003) Ion channel disorders. In Rosenberg RN, Prusiner SB, DiMauro S, Barchi RL, Nestler EJ (eds): The molecular and genetic basis of neurological disease. 3rd edition, Butterworth-Heinemann, Boston, pp. 527-544.
5. Scherer S.S., **Kleopa K.A**., Chance P.F., Benson M. (2003) Neuropathies. In Rosenberg RN, Prusiner SB, DiMauro S, Barchi RL, Nestler EJ (eds): The molecular and genetic basis of neurological disease. 3rd edition, Butterworth-Heinemann, Boston, pp. 435-453.
6. Wrabetz L.M., Feltri M.L., **Kleopa, K.A**., Scherer, S.S. (2004) Inherited neuropathies - clinical, genetic, and biological features. In Lazzarini RL (ed): Myelin Biology and Disorders. Elsevier. pp 905-951.
7. Scherer S.S., **Kleopa K.A.** (2005) X-linked Charcot-Marie-Tooth Disease. In Dyck PJ, Thomas PK (eds): Peripheral Neuropathy. 4th edition, Elsevier Saunders, Philadelphia. pp 1791-1804.
8. **Kleopa K.A**, Scherer, S.S (2005) Familial Neuropathies. In Johnson RT, Griffin JW, McArthur, JC (eds): Current Therapy in Neurological Diseases, 7th edition. Pages: 377-382.
9. **Kleopa K.A.** (2006) Hereditary Spastic Paraparesis. In Lynch DR (ed). Neurogenetics: Scientific and Clinical Advances. Taylor and Francis, New York. pp 231-259.
10. **Kleopa K.A**, Kyriakides T (2007) Cancer and the peripheral Nervous System. In Baehring J, Piepmeier J (eds): Brain Tumors. Practical guide to Diagnosis and Treatment. Informa healthcare, New York. Pp:479-496.
11. Scherer S.S., **Kleopa K.A.**, Benson M. (2007) Neuropathies. In Rosenberg RN, DiMauro S, Paulson HL, Ptáček L, Nestler EJ (eds): The molecular and genetic basis of neurological disease. 4rd edition, Walters Kluwer, p. 428.
12. **Kleopa KA** (2012) Charcot-Marie-Tooth Disease. In Dere E (ed): Gap Junctions in the Nervous System: Physiological and Pathological Roles, p.201-215.
13. Scherer S.S., **Kleopa K.A**., Benson M. (2015) Peripheral Neuropathies. In Rosenberg RN et al (eds): The molecular and genetic basis of neurological disease. 5th edition, Elsevier.
14. **Kleopa KA**. Carpal Tunnel Syndrome. ACP Smart Medicine. http://smartmedicine.acponline.org/content.aspx?gbosId=298. Updated June 24, 2015. doi 10.7326/d624.

15. **Kleopa, KA**, Kagiava, A, Sargiannidou, I (2017) Gene Therapy for CMT inherited neuropathy. In Duan D (ed), *"Muscle Gene Therapy", Springer, 2nd Edition. In press*.

16. Kagiava A, **Kleopa KA** (2018): "Intrathecal delivery of viral vectors for gene therapy". In: Woodhoo A (ed): Myelin: Methods and Protocols, Methods in Molecular Biology, Springer. Intrathecal Delivery of Viral Vectors for Gene Therapy. Methods Mol Biol. 2018;1791:277-285. doi: 10.1007/978-1-4939-7862-5_22.

Invited lectures and presentations (selected from over 50 invited lectures)

2001 Department of Neurology Grant Rounds, University of Pennsylvania: "Genetic disorders of neuromuscular ion channels"

2001 University of Medicine and Dentistry of New Jersey, Neuroscience Grand Rounds: "Inherited neuropathies: clinical aspects and molecular genetics"

2002 MCP-Hahnemann University, Department of Neurology Grand Rounds: "Channellopathies of Nerve and Muscle"

2002 Howard Hughes Medical Institute, Duke University Medical Center, NC: "The molecular base of channelopathies affecting nerve and muscle"

2004 2nd Mediterranean Congress of Neurology, Nicosia, Cyprus: "Recent advances and future directions in the treatment of Charcot-Marie-Tooth neuropathies"

2005 University of Oxford, UK, Institute of Molecular Medicine: "Neuromyotonia sera colocalize with voltage-gated potassium channels in myelinated axons"

2005 Drexel University College of Medicine, Philadelphia, PA, Department of Neurology Grand Rounds: "Inherited Neuropathies: Advances in Genetics and Neurobiology"

2006 University of Crete Medical School, Institute of Molecular Biology and Biotechnology (IMBB): "Neurological disorders of hyperexcitability: the role of potassium channels"

2007 14th Tel Aviv University Alzheimer Conference: "Limbic encephalitis: autoimmune mechanisms and clinical phenotypes"

2007 **European Society for Neurochemistry (ESN) Annual Meeting**: Gap junctions in myelinating cells" May 2007, Salamanca, Spain

2008 **Gordon Research Conference on Myelin, Invited Speaker**: "CNS demyelination in CMT1X patients and in gap junction mutant mice" Il Ciocco, Italy, May 2008

2008 Greek Clinical Neurophysiology Society Annual Meeting: "Evaluation of Nerve damage in the shoulder region", Thessaloniki, Greece, December 2008

2009 **Mediterranean Society of Myology Meeting**: "The effects of CMT1X mutations in myelinating cells". March 2009, Nicosia, Cyprus

2010 Cyprus Neurological Society Annual Meeting, Nicosia: "Myasthenia gravis: Diagnosis and Treatment".

2010 Greek Clinical Neurophysiology Society Annual Meeting: "Diagnostic approach of myopathy with electromyography", Ioannina, Greece, December 2010

2011 1st National Scientific Conference for Rare Disorders, Nicosia: "Diagnostic and therapeutic approach to myasthenia gravis"

5/2012 Eighth Aegean Meeting on Neurological Therapeutics, Heraklion, Crete: “Alterations of glial gap junctions in MS brain and in the EAE model”

11/2012 **XII NeuroMediterranean Congress**, Nicosia, Cyprus: “Paraneoplastic and non-paraneoplastic disorders of the voltage-gated potassium channel complex”

11/2012 3rd International Conference of the Cyprus Society of Human Genetics, Nicosia: “Gene therapy for inherited neuropathy and leukodystrophy”

11/2012 10th World Hellenic Biomedical Congress, University of Nicosia: “Inherited demyelinating disorders of the nervous system”

3/2013 Laboratory of Experimental Neurology and Neuroimmunology, Department of Neurology, Aristotle University of Thessaloniki, Greece, seminar: Emerging roles of glial gap junctions in MS and EAE pathology”

8/2013 Connexin pathology in chronic MS and EAE. **Plenary speaker, 12th MS Workshop** organized by the Japanese Society of Neuroimmunology in Fukuoka, Japan

8/2013 Morvan’s syndrome and autoimmunity to the voltage-gated potassium channel complex. Seminar for the Department of Neurology, Neurological Institute, Kyushu University, Fukuoka, Japan

10/2013 Alterations of glial gap junctions in MS and EAE: a new link between inflammation and neurodegeneration. Hellenic Academy of Neuroimmunology Meeting, Athens

11/2013 The role of gap junctions in inherited and acquired demyelination. 26th Hellenic Neuroscience Society Meeting, Athens

11/2015 Towards a gene therapy approach to treat inherited demyelinating neuropathies, 3rd International Bio-Medical Scientific Cyprus Congress, European University Cyprus, School of Medicine, Nicosia, Cyprus

9/2016 **International Society for Neuroimmunology Annual Meeting**, Jerusalem, Israel. Invited talk: “Involvement of gap junction channels in neuroinflammation”

10/2016 Center for Applied Neurosciences 6th Annual Conference, Univ. of Cyprus: “Insights into molecular mechanisms of neurological disorders using models of neuroinflammation”

10/2016 5rd International Conference of the Cyprus Society of Human Genetics, Nicosia. Invited talk: “Gene Therapy of X-linked Charcot Marie Tooth Disease by Gene Addition”

11/2016 Hellenic Association of Medical Geneticists Meeting, Athens, Greece. Invited talk: “Development of gene therapy for demyelinating neuropathies”

3/2017 “Insights into molecular mechanisms of multiple sclerosis using models of neuroinflammation”. Invited Seminar Talk, University of Nicosia, Nicosia.

7/2017 ***Invited Plenary Speaker*, Peripheral Nerve Society Annual Meeting**. Sitges, Spain: “Intrathecal gene delivery of GJB1 in animal models of CMT1X”.

3/2018 ***Gordon Research Conference on Myelin, Invited Speaker**: Gene therapy approaches targeting myelinating cells, Ventura, California*.

4/2018 Invited Lecture: Myasthenia gravis. Seminar Series of the Department of Pathology. Nicosia General Hospital.

5/2018 Invited Speaker, Clinical Neuroimmunology Meeting, Attica Neurological Sciences Institute: “The role of gap junctions in the Nervous system and demyelinating disorders”, Athens, Greece

7/2018 Invited Speaker, CMT Association (USA) workshop on Gene Therapy for CMT: Opportunities and Challenges. “Targeted Schwann cells to treat CMT1X and CMT4C”. Baltimore, USA

11/2018 Invited Speaker, Annual Meeting of the Medical Geneticists Association of Greece: “New developments in gene therapy for neurological diseases”. Athens, Greece

12/2018 Cyprus Society of Human Genetics Annual Meeting, Nicosia. Invited talk: “Gene addition or silencing approaches to treat inherited neuropathies”

2/2019 Invited Speaker, 5th symposium Current Topics in Myelin Research, Bad Wilhelmshöhe, Kassel, Germany

5/2019 Invited Speaker, CMT Association (USA) Scientific Advisory Board Meeting “Gene therapy for demyelinating CMT”, and “Neurofilament light levels in models of CMT neuropathies”, Philadelphia, USA

10/2019 “The role of gap junctions in inherited and acquired demyelination”. Invited Symposium Speaker, 28th Meeting of the Hellenic Neuroscience Society, Heraklion

11/2019 Invited Speaker, “Gene therapy applications for inherited demyelinating neuropathies”, Neuropathology and Neurogenetics Conference, Polish Academy of Sciences, Warsaw, Poland.

3/2020 ***Invited Plenary Speaker*****,** Netherlands Society for Cell and Gene Therapy Annual Meeting, Lunteren, Netherlands

4/2020 ***Invited Plenary Speaker*****,** UK Neuromuscular Translational Research Conference, UCL-GOSH, London, UK

Presentations in Scientific Conferences *(until December 2019)*

1. Deckert J., Berger W., Kleopa K., Heckers S., Ransmayr G., Wree A., Heinsen H., Beckmann H. and Riederer P. (1991) Visualization of adenosine A1 receptors in human hippocampus. Abstr. Soc. Neurosci. 17: 1546.
2. Deckert J., Berger W., Kleopa K., Heckers S., Ransmayr G., Heinsen H., Wree A., Beckmann H. and Riederer P. (1992) Adenosine receptor antagonists: Interaction with adenosine A1 receptors in human brain. Clin. Neuropharmacol. 15 (Suppl.1): 161.
3. Kleopa K., Berger W., Heckers S., Ransmayr G., Heinsen H., Wree A., Beckmann H., Riederer P. and Deckert J. (1992) Inhibition of (3H)DPCPX binding in human hippocampus by adenosine receptor antagonists. Intern. J. Purine Pyrimidine Res. 3: 84.
4. Deckert J., Berger W., Kleopa K., Heckers S., Kornhuber J., Wree A., Heinsen H., Beckmann H., Ransmayr G. and Riederer P. (1992) Autoradiography of NMDA glutamate and adenosine A1 receptors in human hipppocampus (Methods). Pharmacopsychiatry. 25: 97.
5. Berger W., Deckert J., Kleopa K., Kornhuber J., Heckers S., Ransmayr G., Heinsen H., Wree A., Beckmann H. and Riederer P. (1992) Autoradiographic study of NMDA glutamate and adenosine A1 receptors in the human hippocampus (Results). Pharmacopsychiatry. 25: 80.
6. Deckert J., Berger W., Kleopa K., Heckers S., Ransmayr G., Heinsen H., Beckmann H. and Riederer P. (1993) Adenosine A1 receptors in human hippocampus: relating receptor density to neuron density. In Elsner N, Heisenberg M (eds): Gene Brain Behaviour, Proceedings of the 21th. Goettingen Neurobiology Conference. G.Thieme Verlag, Stuttgart, p.714.
7. Kleopa K.A., Jacobson M. (1998) Gait disorders in elderly patients with idiopathic generalized epilepsy. American Epilepsy Society 52nd Annual Meeting. Epilepsia. 39(suppl.6): 120.
8. Kleopa K.A., Romano G., Neal B., Sherman M., Heiman Patterson T. (1998) Bipap prolongs survival in patients with ALS. 9th International Symposium on ALS/MND, Abstract Book, p. 116.

9. Kleopa K.A., Selak M., Grover W., Kaye E. (1999) Krebs Cycle defects in mitochondrial encephalomyopathies. Neurology. 52 (Suppl 2): A20.
10. Sherman M., Kleopa K.A., Neal B., Heiman-Patterson T. (1999) Noninvasive ventilation improves survival and slows decline of pulmonary function in patients with amyotrophic lateral sclerosis. Am. J. Resp. Intens. Med. 159: A295.
11. Kleopa K.A., Raizen D.M., Friedrich C.A., Brown M.J., Bird S.J. (2000) Acute axonal neuropathy in maple syrup urine disease. AAEM Annual Scientific Meeting, p 95.
12. Yum S., Kleopa K.A., Scherer SS (2001). Diverse expression patterns of connexin32 mutations causing CMTX. 2001 Child Neurology Society Meeting. Annals of Neurology (Suppl 1):S98.
13. Kleopa K.A., Yum S., Scherer S.S. (2002): Molecular mechanisms of hearing loss due connexin gene mutations. 127th Annual Meeting of the American Neurological Association. P 39.
14. Altevogt B.M., Kleopa K.A., Postma F.R., Scherer S.S., Paul D.L. (2002) Distinct expression of Connexin29 by myelinating glial cells of the central and peripheral nervous system. Society for Neuroscience 2002 Annual Meeting.
15. Kleopa K.A., Yum S., Scherer S.S. (2003): Cellular expression of connexin mutations associated with hearing loss. First European Conference on Functional Genomics and Disease, European Science Foundation. Abstract book, p 81.
16. Kleopa K.A., Orthmann, J.L., Enriquez, A, Paul, D.L., Scherer, S.S. (2003) Oligodendrocytes express multiple gap junction proteins that are uniquely distributed. Euroglia 2003 (VI. European Meeting on Glial Cell Function in Health and Disease). Abstract book, P 49.
17. Kleopa K.A., Devaux J., Cooper E.C., Bennet V., Scherer S.S. (2003) KCNQ2 potassium channels at the nodes of Ranvier and initial segments: A novel mechanism of peripheral nerve hyperexcitability. EFNS 7th Annual Meeting. European Journal of Neurology; 10:S31.
18. Papathanasiou E., Papacostas S, Zamba-Papanicolaou E., Kyriakides T., Kleopa K.A., Iliopoulos I., Piperidou C., Pantzaris M. (2003) Neurogenic vestibular evoked potentials in the diagnosis of multiple sclerosis. 19th Congress of the ECTRIMS. Multiple Sclerosis; 9:S127.
19. Devaux JJ, Kleopa KA, Cooper EC, Bennett V, Scherer SS (2003) Anatomical and physiological evidence of KCNQ2 subunits at PNS and CNS nodes. Society for Neuroscience 2003 Annual Meeting.
20. Orthmann J.L., Kleopa K.A., Enriquez A., Scherer S.S. (2003) Oligodendrocytes express multiple gap junction proteins that are uniquely distributed. Society for Neuroscience 2003 Annual Meeting.
21. Kleopa KA, Kkolou E, Kyriakides T (2004) Improved outcome in myasthenia gravis with mycophenolate. 2nd Mediterranean Congress of Neurology.
22. Kleopa KA (2004) Recent advances and future directions in the treatment of Charcot-Marie-Tooth neuropathies. 2nd Mediterranean Congress of Neurology.
23. Kleopa KA, Georgiou D-M, Nicolaou P, Koutsou L, Papathanasiou E, Kyriakides T, Christodoulou K. (2004) A novel PMP22 mutation Ser22Phe in a family with HNPP and CMT1A phenotypes. First European and North American Charcot-Marie-Tooth Consortium Meeting.
24. Kkolou E, Zamba-Papanicolaou E, Kyriakides T, Kleopa KA (2004) Treatment of autoimmune neuromuscular disorders with mycophenolate. EFNS 8th Annual Meeting. European Journal of Neurology; 11 (Suppl. 2), p. 150.
25. Kleopa KA, Kyriacou K, Zamba-Papanicolaou E, Kyriakides T. Reversible inclusion body myositis in celiac disease. EFNS 8th Annual Meeting. European Journal of Neurology; 11 (Suppl. 2), p. 274.
26. Papathanasiou E., Loizides A, Panayiotou P, Papacostas S, Kleopa KA. Ulnar neuropathy at Guyon's Canal: Electrophysiological and surgical findings. EFNS 8th Annual Meeting. European Journal of Neurology; 11 (Suppl. 2), p. 145.
27. Kleopa KA, Lang B, Vincent A, Scherer SS. Neuromyotonia sera colocalize with Kv1.1 and Kv1.2 K+ channels in myelinated axons. Society for Neuroscience 2005 Annual Meeting.
28. Vincent A, Buckley C, Kleopa KA, Scherer SS, Clover L, Jarius S. VGKC antibodies and their roles. XI International Neuromuscular Meeting, 2006.
29. Vincent A, Kleopa, KA, Scherer SS. Potassium channel antibody-associated neurological syndromes. International Society for Neuroimmunology Meeting, Nagoya, Japan, 2006.
30. Kleopa KA, Scherer SS, Vincent A. Neuromyotonia sera target Kv1.6 Shaker-type potassium channels expressed in motor axon terminals. American Neurological Association 131st Annual Meeting, 2006.

31. Kleopa KA, Ahn M, Enriquez A, Scherer SS. Expression of human gap junction protein Connexin31.3 and interactions with Connexin32 mutants. Society for Neuroscience 2006 Annual Meeting
32. Kleopa KA, Gap junctions in myelinating cells. 17th European Society for Neurochemistry Meeting. J Neurochem 2007, 101 (Suppl. 1):18-19.
33. Kleopa KA, Orthmann-Murphy JL, Alevra X, Sargiannidou I, Scherer SS. Mutations in gap junction proteins associated with CNS demyelination. 3rd Aegean Meeting on Neurological Therapeutics, Abstract Book, p 9.
34. Kleopa KA, Orthmann-Murphy JL, Alevra X, Sargiannidou I, Scherer SS. Connexin32 mutations with CNS phenotypes: dominant negative effects on connexin47 expressed in oligodendrocytes. VIII European Glial Cells Meeting 2007, London, UK.
35. Kleopa KA, Orthmann-Murphy JL, Alevra X, Sargiannidou I, Scherer SS. Connexin32 mutations with CNS phenotype impair the expression of connexin47. American Neurological Association Annual Meeting, Washington DC, October 7-10 2007.
36. Sargiannidou I, Reynolds R, Kleopa KA. Expression of gap junction proteins in multiple sclerosis. Gordon Research Conference on Myelin, 2008.
37. Savvaki M, Zoupi L, Karagogeos D, Kleopa KA: Altered juxtaparanodes in the adult central nervous system of TAG-1 deficient mice. Federation of European Neuroscience Societies (FENS) Forum Meeting 2008, Geneva, Switzerland.
38. Sargiannidou S, Vavlitou N, Hadjisavvas A, Kyriacou K, Scherer SS, Kleopa KA. The effects of CMT1X mutations in myelinating cells. The Cyprus Society of Human Genetics Meeting 2008, Nicosia.
39. Kleopa KA, Sargiannidou I, Vavlitou N, Hadjisavvas A, Kyriacou K, Scherer SS: Transgenic expression of CMT1X mutations with CNS manifestations in oligodendrocytes. Society for Neuroscience 2008 Annual Meeting, Washington DC.
40. Kleopa KA. Diagnosis and treatment of myasthenia gravis in Cyprus. Mediterranean Society of Myology Meeting, Nicosia, Cyprus, 20-22/03/2009.
41. Kleopa KA. The effects of CMT1X mutations in myelinating cells. Mediterranean Society of Myology Meeting, Nicosia, Cyprus, 20-22/03/2009
42. Sargiannidou I, Vavlitou N, Markoullis K, Hadjisavvas A, Kyriacou K, Scherer SS, Kleopa KA: Loss of gap junctions in myelinating cells causes progressive demyelination and early axonopathy. ELA Research Foundation 2nd Scientific Meeting, 26-27 June 2009, Luxembourg.
43. Vavlitou N, Sargiannidou I, Markoullis K, Hadjisavvas A, Kyriacou K, Scherer SS, Kleopa KA: Loss of Cx32 gap junctions in Schwann cells with CMT1X mutations causes progressive demyelination and early axonopathy. Peripheral Nerve Society Meeting, July 2009, Wuerzburg, Germany.
44. Sargiannidou I, Vavlitou N, Markoullis K, Kyriacou K, Scherer SS, Kleopa KA: Axonal degeneration in mouse models of CMT1X neuropathy. Glial Cell Meeting, September 2009, Paris, France.
45. Irani S, Waters P, Kleopa KA, Lang B, Vincent A: Antibodies to components of the voltage-gated potassium channel- associated complex: LGI1 and CASPR2 as antigenic targets in limbic encephalitis, Morvan's and neuromyotonia. American Academy of Neurology 2010 Annual Meeting (LBS.001), Toronto, Canada (Neurology 2010, Vol 75, page 379).
46. Sargiannidou I, Vavlitou N, Markoullis K, Kyriacou K, Scherer SS, Kleopa KA: Axonal degeneration precedes demyelination of peripheral nerves in mice lacking Cx32 gap junctions in the myelin sheath. Accepted for oral presentation at the International Conference on Neuromuscular Disorders, Naples, Italy, 17-22 July 2010.
47. Markoullis K, Sargiannidou I, Hadjisavvas A, Reynolds R, Kleopa KA: Differential Expression of Glial Gap Junction proteins during the progression of experimental autoimmune encephalomyelitis. International Congress of Neuroimmunology, 26-30/10/2010, Sitges, Spain.
48. Markoullis K, Sargiannidou I, Gardner C, Hadjisavvas A, Reynolds R, Kleopa KA: The role of glial gap junctions in EAE pathology. Myelin Satellite Meeting, International Society for Neurochemistry, August 2011, Chania, Greece.
49. Kleopa, KA, Markoullis K, Sargiannidou, I, Schiza N, Hadjisavvas A, Roncaroli F, Reynolds R: Oligodendrocyte gap junction loss in multiple sclerosis and in experimental autoimmune encephalomyelitis (2012). Oral presentation, European Federation of Neurological Societies (EFNS) annual meeting, 8-11/9/2-12, Stockholm, Sweden, European Journal of Neurology 19 (Suppl. 1), 22-89.

50. Sargiannidou I, Bashardes S, Richter J, Kagiava A, Schiza N, Gritti A, Christodoulou C, Kleopa KA. Gene therapy for inherited neuropathy. Poster, XII NeuroMediterranean Congress, November 2012, Nicosia, Cyprus.
51. Schiza N, Sargiannidou I, Kleopa KA: Dysregulation of axonal cytoskeleton in a mouse model of X-linked Charcot-Marie-Tooth Disease. 3rd International Conference of the Cyprus Society of Human Genetics, November 2012, Nicosia, Cyprus.
52. Kagiava A, Sargiannidou I, Bashardes S, Richter J, Christodoulou C, Gritti A, Kleopa KA. Gene therapy for hypomyelinating leukodystrophy. 23rd European Neurological Society Meeting Barcelona 2013, oral presentation. J Neurol (2013) 260 (Suppl 1): S40.
53. Sargiannidou I, Kagiava A, Bashardes S, Richter J, Schiza N, Christodoulou C, Gritti A, Kleopa KA. Efficient lentiviral gene delivery to Schwann cells. 2013 Meeting of the Peripheral Nerve Society, Saint-Malo, France. J Periph Nerv System Vol. 18, Suppl. 2, S103.- *selected oral presentation.*
54. Schiza N, Sargiannidou I, Kleopa KA. Altered molecular architecture of non-compact myelin in a CMT1X model: implications for axonal pathology. 2013 Meeting of the Peripheral Nerve Society, Saint-Malo, France. J Periph Nerv System Vol. 18, Suppl. 2, S103.
55. Markoullis K, Sargiannidou I, Schiza N, Reynolds R, Kleopa KA. Alterations of Gray Matter Gap Junctions in Multiple Sclerosis and in EAE. Euroglia Meeting, Berlin. GLIA Vol. 61, Issue Suppl S1, pages S49–S216, July 2013.
56. Kagiava A, Sargiannidou I, Bashardes S, Richter J, Schiza N, Christodoulou C, Gritti A, Kleopa KA. Oligodendrocyte-targeted gene therapy to treat leukodystrophy. Euroglia Meeting, Berlin. GLIA Vol. 61, Issue Suppl S1, pages S49–S216, July 2013.
57. Sargiannidou I., Kagiava A., Bashiardes S., Richter J., Schiza N., Christodoulou C., Gritti A., Kleopa K.A. *Efficient lentiviral gene delivery to schwann cells*; 10th Euroglia Meeting; July 2013; Berlin-Germany.
58. Schiza N, Sargiannidou I, Kleopa KA. *The role of myelin gap junction in the regulation of axonal cytoskeleton*; 10th Euroglia Meeting; July 2013; Berlin-Germany.
59. Schiza N, Sargiannidou I, Kagiava A, Karaiskos C, Lapathitis G, Kleopa KA. *Transgenic rescue of oligodendrocyte gap junctions in a mouse model of hypomyelinating leukodystrophy*; 26th Meeting of the Hellenic Society for Neuroscience; November 2013; Athens-Greece)
60. Olympiou M., Kagiava A., Sargiannidou I., Schiza N., Karaiskos C., Kleopas K.A. *The effect of inflammation on glial gap junctions*; 26th Meeting of the Hellenic Society for Neuroscience; November 2013; Athens-Greece
61. Kagiava A., Sargiannidou I., Bashiardes S., Richter J., Schiza N., Christodoulou C., Gritti A. and Kleopas K.A. *A quick method for targeted gene delivery to treat leukodystrophy and inherited neuropathies*; 26th Meeting of the Hellenic Society for Neuroscience; November 2013; Athens-Greece
62. Sargiannidou I., Kagiava A., Bashiardes S., Richter J., Schiza N., Christodoulou C., Gritti A., Kleopa K.A. Gene therapy in a mouse model of CMT1X neuropathy using a lentiviral vector. American Academy of Neurology Annual Meeting, Philadelphia, USA, April 2014. *Selected for oral presentation.*
63. Schiza N, Sargiannidou I, Kagiava A, Karaiskos C, Kleopa KA. *Transgenic replacement of oligodendrocyte gap junctions rescues the phenotype of a hypomyelinating leukodystrophy model*; 9th FENS Forum; July 2014; Milan- Italy
64. Kagiava A., Sargiannidou I., Bashiardes S., Richter J., Schiza N., Christodoulou C., Gritti A., Kleopa K.A. *Gene delivery targeted to myelinating cells to treat inherited neuropathies and leukodystrophy*; 9th FENS Forum; July 2014; Milan-Italy.
65. Schiza N, Sargiannidou I, Kagiava A, Karaiskos C, Kleopa KA. *Transgenic replacement of oligodendrocyte gap junctions rescues the phenotype of a hypomyelinating leukodystrophy model*; 4th International Conference of the Cyprus Society of Human Genetics, October 2014, Nicosia-Cyprus
66. Sargiannidou I., Kim G., Kyriakoudi S., Eun B., Kleopa K.A: A start codon CMT1X mutation associated with transient encephalomyelitis causes complete loss of Cx32 function. 4th International Conference of the Cyprus Society of Human Genetics, October 2014, Nicosia-Cyprus
67. Sargiannidou I., Kagiava A., Bashiardes S., Richter J., Schiza N., Christodoulou C., Kleopa K.A. *Intraneural gene delivery improves nerve pathology in a mouse model of X-linked CMT*; October 2014; Nicosia-Cyprus- Selected for dual /oral presentation- Best poster Award.

68. Olympiou M, Sargiannidou I., Kagiava A., Schiza N., Karaiskos C, Kleopa K.A. Modeling CNS phenotypes of X-linked CMT by LPS-induced inflammation. International Society for Neuroimmunology, Mainz, Germany, Nov 2014
69. Kleopa KA, Kagiava A., Bashiardes S., Richter J., Schiza N., Christodoulou C, Sargiannidou I.. Intraneural and intrathecal gene delivery using a Schwann cell targeted lentiviral vector for treating inherited demyelinating neuropathies. Accepted for oral presentation, European Academy of Neurology 1st Annual Meeting, Berlin, June 20-23, 2015. (*Awarded with the European Academy of Neurology Investigator Award 2015 from the Scientific Subspecialty Panel on Neuropathies*)
70. K. Markoullis, I. Sargiannidou, C. Papaneophytou, N. Schiza, F. Roncaroli, R. Reynolds, C. Abrams, K. Kleopa: Junctions and gaps: connexin pathology in multiple sclerosis and EAE. Symposium presentation, 12th Euroglia Meeting, Bilbao, Spain, July 15-18, 2015. *GLIA 63:E58 (2015)*.
71. C. Papaneophytou, I. Sargiannidou, E. Georgiou, C. Abrams, K. Kleopa. Roles of Cx47 and Cx32 in experimental autoimmune encephalomyelitis. Poster presentation, 12th Euroglia Meeting, Bilbao, Spain, July 15-18, 2015. *GLIA 63:E347 (2015).*
72. Georgiou E, Sidiropoulou K, Richter J, Papaneophytou C, Sargiannidou I, Kagiava A, von Jonquieres G, Christodoulou C, Klugmann M, Kleopa KA. Gene delivery to oligodendrocytes reestablishes gap junctions and rescues a hypomyelinating leukodystrophy model. European Academy of Neurology Annual Meeting, Copenhagen, May 2016.
73. Papaneophytou C, Georgiou E, Sargiannidou I, Abrams CK, Kleopa KA. Loss of oligodendrocyte connexins aggravates experimental autoimmune encephalomyelitis. 13 th International Society for Neuroimmunology Gongress, Jerusalem, Israel, 26-29 September 2016
74. Kyriakoudi S, Sargiannidou I, Kagiava A, Kleopa K A. Screening for interactions between virally delivered Cx32 and neuropathy-associated mutants: towards a gene therapy for CMT1X. 6th International Charcot-Marie-Tooth and Related Neuropathy Consortium (CMTR) Meeting, Venice 8 -10 September 2016.
75. Kagiava A., Karaiskos C., Richter J., Sargiannidou I., Christodoulou C., Kleopa KA., "Intrathecal gene therapy in a neuropathy model expressing a CMT1X mutation"; 6th International Charcot-Marie-Tooth And Related Neuropathy Consortium (CMTR) Meeting (September 8-10, 2016, Venice-Italy), *Selected oral presentation.*
76 Kagiava A, Karaiskos C, Richter J, Tryfonos C, Lapathitis G, Sargiannidou I, Christodoulou C, Kleopa KA: Intrathecal gene therapy in different mutant mouse models of CMT1X. Peripheral Nerve Society (PNS) Meeting, Sitges, Spain, July 8-12, 2017.
77 Schiza N, Markoullis K, Richter J, Tryfonos C, Kagiava A, Sargiannidou I, Christodoulou C, Kleopa KA. A Gene therapy approach for treating CMT4C neuropathy. Peripheral Nerve Society (PNS) Meeting, Sitges, Spain, July 8-12, 2017.
78 Development of an intrathecal gene therapy approach in models of cmt1x inherited neuropathy. Kagiava A, Karaiskos C, Richter J, Tryfonos C, Lapathitis G, Sargiannidou I, Christodoulou C, Kleopa KA. Hellenic Society for Neuroscience Meeting, Athens, Dec. 8-10, 2017
The functional role of connexins inperipheral myelinated fibers in health and disease
79 Tympanidou M, Kagiava A, Kleopa KA. Hellenic Society for Neuroscience Meeting, Athens, Dec. 8-10, 2017
Gene therapy approach using a lentiviral vector for treating Charcot-Marie-Tooth Type 4C. Schiza N, Richter J, Tryfonos C, Kagiava A, Sargiannidou I, Christodoulou C, Kleopa KA.
80 Hellenic Society for Neuroscience Meeting, Athens, Dec. 8-10, 201
Schiza_N., Georgiou E., Richter J, Tryfonos C, Kagiava A., Sargiannidou I., Christodoulou C, Kleopa K.A. "A gene therapy approach for treating Charcot-Marie-Tooth disease type 4C";
81 2018 PNS Annual Meeting (July 22-25, 2018, Baltimore-USA)
Kagiava A., Richter J., Tryfonos C., Karaiskos C., Sargiannidou I., Christodoulou C., Kleopa K.A. "Gene replacement therapy for CMT1X neuropathy"; 2018 PNS Annual Meeting (July 22-25,
82 2018, Baltimore-USA)
Stavrou M., Sargiannidou I., Kagiava A., Richter J., Tryfonos C., Karaiskos C., Lapathitis G. and Kleopa K.A. "A Gene Silencing Approach to Treat Charcot-Marie-Tooth Disease Type 1A"; 2018
83 PNS Annual Meeting (July 22-25, 2018, Baltimore-USA)
Schiza_N., Georgiou E., Richter J, Tryfonos C, Kagiava A., Sargiannidou I., Christodoulou C, Kleopa K.A. "A gene therapy approach for treating Charcot-Marie-Tooth disease type 4C"; 6th International Multithematic Bio-Medical Congress (IMBMC) (November 15-17, 2018, Nicosia
84 Cyprus)

Kagiava A., Richter J., Tryfonos C., Karaiskos C., Sargiannidou I., Christodoulou C., Kleopa K.A.
85 "Gene replacement therapy for CMT1X neuropathy"; 6th International Multithematic Bio-Medical Congress (IMBMC) (November 15-17, 2018, Nicosia Cyprus)
Stavrou M., Sargiannidou I., Kagiava A., Richter J., Tryfonos C., Karaiskos C., Lapathitis G. and Kleopa K.A. "A Gene Silencing Approach to Treat Charcot-Marie-Tooth Disease Type 1A"; 6th
86 International Multithematic Bio-Medical Congress (IMBMC) (November 15-17, 2018, Nicosia Cyprus)
87 Kagiava A., Karaiskos C., Richter J., Tryfonos C., Rossor A., Reilly M.M., Sargiannidou I., Christodoulou C., Kleopa K.A. Gene therapy after onset of neuropathy provides therapeutic benefit in a model of CMT1X. Accepted for platform presentation at the upcoming 2019 AAN Annual Meeting (May 4-10, Philadelphia, USA).
88 Kagiava A., Karaiskos C., Richter J., Tryfonos C., Rossor A., Reilly M.M., Sargiannidou I., Christodoulou C., Kleopa K.A "Gene replacement therapy for CMT1X neuropathy"; 2019 PNS Annual Meeting (June 22-26, 2019, Genova-Italy)
89 Marina Stavrou, Irene Sargiannidou, Alexia Kagiava, Jan Richter, Christina Tryfonos, Christina Christodoulou, Christos Karaiskos, George Lapathitis and Kleopas A. Kleopa. Testing An shRNA Gene Silencing Approach In A Mouse Model Of Charcot-Marie-Tooth Disease Type 1A. 2019 Peripheral Nerve Society Annual Meeting annual meeting held in Genoa, Italy